# EDGAR Filing Document

**Accession Number:** 0001645460
**File Stem:** 0001193125-25-292093
**Filing Date:** 2025-11
**Character Count:** 6499
**Document Hash:** 09da08d842610a6145c1f8c6e59fd319
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-292093.hdr.sgml**: 20251124

**ACCESSION NUMBER**: 0001193125-25-292093

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 37

**CONFORMED PERIOD OF REPORT**: 20251124

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20251124

**DATE AS OF CHANGE**: 20251124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cue Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001645460
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473324577
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38327
- **FILM NUMBER:** 251509636

**BUSINESS ADDRESS:**
- **STREET 1:** 40 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135
- **BUSINESS PHONE:** 617-949-2680

**MAIL ADDRESS:**
- **STREET 1:** 40 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Imagen Biopharma, Inc.
- **DATE OF NAME CHANGE:** 20150617

?xml version='1.0' encoding='ASCII'? 8-K

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported):** November 24, 2025

------

Cue Biopharma, Inc.

**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-38327 | 47-3324577 |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| 40 Guest Street<br>Boston**,** Massachusetts | 02135<br>**(Zip Code)** |
| **(Address of principal executive offices)** |  |

---

**(**617**)** 949-2680

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report.)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

------

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.001 per share | CUE | Nasdaq **Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure**<br>|

---

On November 24, 2025, Cue Biopharma, Inc. (the "Company") made publicly available on its website an updated corporate presentation. A copy of the presentation is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 99.1 | [<u>Corporate Presentation, dated November 24, 2025</u>](cue-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;**Cue Biopharma, Inc.** | &nbsp;&nbsp;&nbsp;&nbsp;**Cue Biopharma, Inc.** |
| Date: November 24, 2025 | By: | /s/ Usman Azam |
|  | Name: Usman Azam | Name: Usman Azam |
|  | Title: President and Chief Executive Officer | Title: President and Chief Executive Officer |

---

------

## Exhibit 99.1

Exhibit 99.1

![img239719762_0.jpg](img239719762_0.jpg)

![img239719762_1.jpg](img239719762_1.jpg)

------

![img239719762_2.jpg](img239719762_2.jpg)![img239719762_3.jpg](img239719762_3.jpg)

------

![img239719762_4.jpg](img239719762_4.jpg)![img239719762_5.jpg](img239719762_5.jpg)

------

![img239719762_6.jpg](img239719762_6.jpg)![img239719762_7.jpg](img239719762_7.jpg)

------

![img239719762_8.jpg](img239719762_8.jpg)![img239719762_9.jpg](img239719762_9.jpg)

------

![img239719762_10.jpg](img239719762_10.jpg)![img239719762_11.jpg](img239719762_11.jpg)

------

![img239719762_12.jpg](img239719762_12.jpg)![img239719762_13.jpg](img239719762_13.jpg)

------

![img239719762_14.jpg](img239719762_14.jpg)

![img239719762_15.jpg](img239719762_15.jpg)

------

![img239719762_16.jpg](img239719762_16.jpg)

------

![img239719762_17.jpg](img239719762_17.jpg)![img239719762_18.jpg](img239719762_18.jpg)

------

![img239719762_19.jpg](img239719762_19.jpg)![img239719762_20.jpg](img239719762_20.jpg)

------

![img239719762_21.jpg](img239719762_21.jpg)![img239719762_22.jpg](img239719762_22.jpg)

------

![img239719762_23.jpg](img239719762_23.jpg)![img239719762_24.jpg](img239719762_24.jpg)

------

![img239719762_25.jpg](img239719762_25.jpg)

------